Beovu was intended to maintain Novartis' anti-VEGF franchise once Lucentis starts to fade, and had been predicted to become a $2.5 billion product before the safety issue emerged. Image Phil Taylor ...
A “worst case scenario” where Beovu is withdrawn from the market cuts earnings per share by 4% and would add to Novartis’ woes following the phase 3 trial failure of fevipiprant for asthma.
Who Are the Leading Players in the Beovu Brolucizumab Market? Novartis AG is a key player at the forefront of the Beovu brolucizumab market, driving innovation and business expansion. How Is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results